150
Participants
Start Date
April 23, 2025
Primary Completion Date
March 31, 2026
Study Completion Date
December 31, 2026
TQB2825 injection +R-CHOP regimen
"R-CHOP is a cancer treatment regimen that uses a combination of five drugs to treat non-Hodgkin lymphoma, e.g., Rituximab+Cyclophosphamide+Doxorubicin Hydrochloride+Vincristine+Prednisone (R-CHOP).~TQB2825 Injection: TQB2825 is a bispecific antibody targeting the cluster of differentiation 20 (CD20) receptor on tumor cells and the cluster of differentiation 3 (CD3) receptor on T cells.~Rituximab: A monoclonal antibody that binds to the CD20 antigen on the surface of B cells.~Cyclophosphamide: An alkylating agent that inhibits the synthesis of DNA and proteins in cancer cells.~Doxorubicin Hydrochloride: An antineoplastic antibiotic that inhibits the synthesis of DNA and RNA.~Vincristine: A microtubule inhibitor that blocks the normal function of microtubules during cell division.~Prednisone: A corticosteroid drug with anti-inflammatory, anti-allergic, immunosuppressive, and anti-cancer effects.~TQB2825 injection + GemOx (Gemcitabine + Oxaliplatin)"
TQB2825 injection + GemOx
"TQB2825 Injection: TQB2825 is a bispecific antibody targeting the CD20 receptor on tumor cells and the CD3 receptor on T cells.~Gemcitabine: A nucleoside analog that inhibits DNA synthesis. Oxaliplatin: A platinum-based chemotherapy drug that forms cross-links with DNA, inhibiting DNA replication and transcription."
NOT_YET_RECRUITING
Yantai Yuhuangding Hospital, Yantai
NOT_YET_RECRUITING
Shanxi Cancer hospital, Taiyuan
RECRUITING
Beijing Cancer Hospital, Beijing
NOT_YET_RECRUITING
The second Hospital of dalian, Dalian
NOT_YET_RECRUITING
The First Hospital of Jilin University, Changchun
NOT_YET_RECRUITING
Harbin Medical University Cancer Hospital, Harbin
NOT_YET_RECRUITING
Fudan university shanghai cancer center, Shanghai
NOT_YET_RECRUITING
Jiangsu Provincial People's Hospital, Nanjing
NOT_YET_RECRUITING
The Affiliated Hospital of Xuzhou Medical University, Xuzhou
NOT_YET_RECRUITING
The First Affiliated Hospital of Bengbu Medical College, Bengbu
RECRUITING
Maanshan People's Hospital, Ma’anshan
NOT_YET_RECRUITING
Affiliated Cancer Hospital of Shandong First Medical University, Jinan
NOT_YET_RECRUITING
People's Hospital of Tianjin (City), Tianjin
NOT_YET_RECRUITING
Tianjin Medical University Cancer Hospital, Tianjin
NOT_YET_RECRUITING
Jiangxi Canser Hospital, Nanchang
NOT_YET_RECRUITING
Fujian Cancer Hospital, Fuzhou
RECRUITING
The Second Affiliated Hospital of Fujian Medical University, Quanzhou
NOT_YET_RECRUITING
Hubei Cancer Hospital, Wuhan
RECRUITING
Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou
NOT_YET_RECRUITING
Puyang Oilfield General Hospital, Puyang
NOT_YET_RECRUITING
Sun Yat-sen University Cancer Center, Guangzhou
NOT_YET_RECRUITING
Liuzhou People's Hospital, Liuzhou
NOT_YET_RECRUITING
The Affiliated Hospital of Southwest Medical University, Luzhou
NOT_YET_RECRUITING
The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an
NOT_YET_RECRUITING
Gansu Provincial Cancer Hospital, Lanzhou
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
INDUSTRY